SG11202000298VA - Antibodies to madcam - Google Patents
Antibodies to madcamInfo
- Publication number
- SG11202000298VA SG11202000298VA SG11202000298VA SG11202000298VA SG11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- madcam
- international
- disclosure
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo Ho VIII Inv n (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/014572 Al (43) International Publication Date 17 January 2019 (17.01.2019) WIPO I PCT (51) International Patent Classification: CO7K 16/28 (2006.01) A61P 29/00 (2006.01) A61P 37/06 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/042052 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 13 July 2018 (13.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/532,809 14 July 2017 (14.07.2017) US (71) Applicant: PFIZER, INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor: ANDERSON, Karin; c/o Pfizer, Inc., 235 East 42nd Street, New York, NY 10017 (US). (74) Agent: MENDEZ, Julio, J. et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: ANTIBODIES TO MADCAM (57) : The present disclosure relates to antibodies including human antibodies and antigen- binding portions thereof that specifi- cally bind to MAdCAM, preferably human MAdCAM and that func- tion to inhibit MAdCAM. The disclosure also relates to human an- ti-MAdCAM antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, de- rivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglob- ulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclo- sure also relates to methods of making human anti- MAdCAM an- tibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The disclosure also relates to transgenic animals or plants comprising nu- clpeic acid molecules of the disclosure. Figure IA Figure 1J r Figure IL Figure IB Figure C [MI Figure 10 Figure IF Figure IC A rir.rr. _w,rerrrrri Figure IR Figure IH
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762532809P | 2017-07-14 | 2017-07-14 | |
PCT/US2018/042052 WO2019014572A1 (en) | 2017-07-14 | 2018-07-13 | Antibodies to madcam |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000298VA true SG11202000298VA (en) | 2020-02-27 |
Family
ID=63209653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000298VA SG11202000298VA (en) | 2017-07-14 | 2018-07-13 | Antibodies to madcam |
Country Status (24)
Country | Link |
---|---|
US (2) | US20190169291A1 (en) |
EP (1) | EP3652211A1 (en) |
JP (1) | JP7160491B2 (en) |
KR (1) | KR20200028006A (en) |
CN (1) | CN111032694B (en) |
AR (1) | AR112336A1 (en) |
AU (1) | AU2018300189A1 (en) |
BR (1) | BR112020000698A2 (en) |
CA (1) | CA3069914A1 (en) |
CL (1) | CL2020000102A1 (en) |
CO (1) | CO2020000352A2 (en) |
CR (1) | CR20200076A (en) |
CU (1) | CU20200002A7 (en) |
DO (1) | DOP2020000005A (en) |
EA (1) | EA202090286A1 (en) |
EC (1) | ECSP20011317A (en) |
IL (1) | IL272015A (en) |
MA (1) | MA48241A1 (en) |
NI (1) | NI202000004A (en) |
PE (1) | PE20200616A1 (en) |
PH (1) | PH12020500100A1 (en) |
SG (1) | SG11202000298VA (en) |
TW (1) | TW201920266A (en) |
WO (1) | WO2019014572A1 (en) |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US20040010810A1 (en) | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
ES2139598T3 (en) | 1990-07-10 | 2000-02-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
AU664976B2 (en) | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DK0564531T3 (en) | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE69233254T2 (en) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
JPH05244982A (en) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
AU5675794A (en) | 1992-12-15 | 1994-07-04 | Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
ATE193301T1 (en) | 1993-03-09 | 2000-06-15 | Genzyme Corp | METHOD FOR ISOLATION OF PROTEINS FROM MILK |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5698679A (en) | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
AU4986296A (en) | 1995-02-10 | 1996-08-27 | Leukosite Incorporated | Mucosal vascular addressins and uses thereof |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
AU705616B2 (en) | 1995-04-21 | 1999-05-27 | Cell Genesys, Inc. | Generation of large genomic DNA deletions |
ATE390933T1 (en) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1999045031A2 (en) | 1998-03-03 | 1999-09-10 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
DE69940503D1 (en) | 1998-05-13 | 2009-04-16 | Genentech Inc | DIAGNOSIS AND TREATMENT OF HEPATIC DISEASES |
US7090845B2 (en) | 1998-05-13 | 2006-08-15 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
AP1590A (en) | 1998-12-23 | 2006-03-14 | Pfizer | Human monoclonal antibodies to CTLA-4. |
JP2003533968A (en) | 1999-09-03 | 2003-11-18 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
JP2003089656A (en) | 2001-09-19 | 2003-03-28 | Nippon Kayaku Co Ltd | Inhibitory agent against immune response caused by transplantation |
CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
WO2003072040A2 (en) | 2002-02-25 | 2003-09-04 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
US20070202097A1 (en) | 2003-03-10 | 2007-08-30 | Krissansen Geoffrey W | Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof |
CN102258464A (en) | 2003-04-04 | 2011-11-30 | 健泰科生物技术公司 | High concentration antibody and protein formulations |
BR122021007893B1 (en) | 2004-01-09 | 2022-04-12 | Pfizer Inc. | Monoclonal antibody, or antigen-binding fraction thereof that specifically binds to madcam, pharmaceutical composition, vaccine and diagnostic kit |
KR20070009581A (en) | 2004-02-06 | 2007-01-18 | 엘란 파마슈티칼스, 인크. | Method and compositions for treating tumors and metastatic disease |
BRPI0608855A2 (en) | 2005-03-08 | 2010-02-02 | Pharmacia & Upjohn Co Llc | anti - madcam antibody compositions process for their preparation and use of anti - madcam antibody |
CN101325968B (en) * | 2005-03-08 | 2014-04-23 | 辉瑞产品公司 | Anti-CTLA-4 antibody compositions |
EP1904103A2 (en) | 2005-07-08 | 2008-04-02 | Pfizer Limited | Use of anti-madcam antibodies for the treatment of coeliac disease and tropical sprue |
EP1904531B1 (en) | 2005-07-08 | 2010-10-06 | Pfizer Limited | Madcam antibodies |
WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
WO2007007162A1 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
US8081772B2 (en) | 2008-11-20 | 2011-12-20 | Gentex Corporation | Vehicular microphone assembly using fractional power phase normalization |
CN105143876B (en) | 2013-03-27 | 2018-04-20 | 豪夫迈·罗氏有限公司 | Biomarker is used to assess the purposes with 7 integrin antagonists of β treatment gastrointestinal inflammatory illness |
CA2916283A1 (en) | 2015-01-09 | 2016-07-09 | Pfizer Inc. | Dosage regimen for madcam antagonists |
-
2018
- 2018-07-13 AU AU2018300189A patent/AU2018300189A1/en active Pending
- 2018-07-13 EA EA202090286A patent/EA202090286A1/en unknown
- 2018-07-13 SG SG11202000298VA patent/SG11202000298VA/en unknown
- 2018-07-13 KR KR1020207004168A patent/KR20200028006A/en not_active Application Discontinuation
- 2018-07-13 WO PCT/US2018/042052 patent/WO2019014572A1/en unknown
- 2018-07-13 AR ARP180101961 patent/AR112336A1/en unknown
- 2018-07-13 CR CR20200076A patent/CR20200076A/en unknown
- 2018-07-13 EP EP18755583.4A patent/EP3652211A1/en active Pending
- 2018-07-13 TW TW107124340A patent/TW201920266A/en unknown
- 2018-07-13 BR BR112020000698-0A patent/BR112020000698A2/en not_active IP Right Cessation
- 2018-07-13 MA MA48241A patent/MA48241A1/en unknown
- 2018-07-13 CN CN201880056875.XA patent/CN111032694B/en active Active
- 2018-07-13 PE PE2020000060A patent/PE20200616A1/en unknown
- 2018-07-13 JP JP2020501133A patent/JP7160491B2/en active Active
- 2018-07-13 CA CA3069914A patent/CA3069914A1/en active Pending
- 2018-07-13 US US16/035,178 patent/US20190169291A1/en not_active Abandoned
- 2018-07-13 CU CU2020000002A patent/CU20200002A7/en unknown
-
2020
- 2020-01-09 DO DO2020000005A patent/DOP2020000005A/en unknown
- 2020-01-13 NI NI202000004A patent/NI202000004A/en unknown
- 2020-01-13 IL IL272015A patent/IL272015A/en unknown
- 2020-01-13 CL CL2020000102A patent/CL2020000102A1/en unknown
- 2020-01-14 PH PH12020500100A patent/PH12020500100A1/en unknown
- 2020-01-14 CO CONC2020/0000352A patent/CO2020000352A2/en unknown
- 2020-02-13 EC ECSENADI202011317A patent/ECSP20011317A/en unknown
-
2021
- 2021-06-04 US US17/338,991 patent/US11802156B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CO2020000352A2 (en) | 2020-04-13 |
US11802156B2 (en) | 2023-10-31 |
ECSP20011317A (en) | 2020-12-31 |
AU2018300189A1 (en) | 2020-01-30 |
EP3652211A1 (en) | 2020-05-20 |
JP7160491B2 (en) | 2022-10-25 |
EA202090286A1 (en) | 2020-05-12 |
MA48241A1 (en) | 2021-03-31 |
US20220119521A1 (en) | 2022-04-21 |
IL272015A (en) | 2020-02-27 |
PE20200616A1 (en) | 2020-03-11 |
CR20200076A (en) | 2020-06-10 |
CU20200002A7 (en) | 2020-11-30 |
DOP2020000005A (en) | 2021-02-15 |
BR112020000698A2 (en) | 2020-07-14 |
KR20200028006A (en) | 2020-03-13 |
NI202000004A (en) | 2020-03-30 |
TW201920266A (en) | 2019-06-01 |
PH12020500100A1 (en) | 2020-09-14 |
US20190169291A1 (en) | 2019-06-06 |
CL2020000102A1 (en) | 2020-10-09 |
CN111032694A (en) | 2020-04-17 |
CN111032694B (en) | 2024-03-08 |
AR112336A1 (en) | 2019-10-16 |
WO2019014572A1 (en) | 2019-01-17 |
JP2020533953A (en) | 2020-11-26 |
CA3069914A1 (en) | 2019-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201909499QA (en) | Humanized antigen-binding domains against cd19 and methods of use | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201810465RA (en) | Compositions and methods related to engineered fc constructs | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |